Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia | Zendy

Elizabeth Alexander | Zendy; Lisa Goldberg | Zendy; Anita Das | Zendy; Gregory J. Moran | Zendy; Christian Sandrock | Zendy; Leanne B. Gasink | Zendy; Patricia Spera | Zendy; Carolyn Sweeney | Zendy; Susanne Paukner | Zendy; Wolfgang W. Wicha | Zendy; Steven P Gelone | Zendy; Jennifer Schranz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia

Author(s) -

Elizabeth Alexander,

Lisa Goldberg,

Anita Das,

Gregory J. Moran,

Christian Sandrock,

Leanne B. Gasink,

Patricia Spera,

Carolyn Sweeney,

Susanne Paukner,

Wolfgang W. Wicha,

Steven P Gelone,

Jennifer Schranz

Publication year - 2019

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2019.15468

Subject(s) - medicine , moxifloxacin , regimen , randomized controlled trial , community acquired pneumonia , adverse effect , clinical trial , population , pneumonia , clinical endpoint , pediatrics , antibiotics , environmental health , microbiology and biotechnology , biology

New antibacterials are needed to treat community-acquired bacterial pneumonia (CABP) because of growing antibacterial resistance and safety concerns with standard care.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research